DFTX — Definium Therapeutics Inc. stock price and chart

Share this page

DFTX

$32.10-6.30%

as of close, Oct 16, 2026

☾ AH $32.10 -6.30%

Definium Therapeutics Inc.Stock · HealthcareRussell 2000 0.2%Nasdaq Composite 0.009%Russell 3000 0.008%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeSEEEE

20162019202120242026

10.020.030.040.050.060.0020.0M40.0M$32.10

2026-10-16

Price$32.10

MA20$38.65

MA50$25.45

Vol9.4M

What would $1,000 invested in DFTX be worth today? →

DFTX returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $32.10
YTD price return: +139.73%
YTD total return: +139.73%
Next earnings: Nov 5, 2026
Market cap: 4.3B2021-06 1.4B2026-10 4.3B+204.4% over the window
Enterprise value: 3.3B
Shares outstanding: 134.4M2021-06 27.4M2026-06 134.4M+390.6% over the window
52W low: $10.47
52W high: $49.70
From 52W high: -35.41%
From 52W low: +206.74%
52W range: 55%

Volume

Rel volume: 0.83×
30D volume: 2.3M
30D $ vol: 86.6M

Fundamentals

EPS (ttm): -$3.482021-12 -$3.402026-06 -$3.48+2.4% over the window
FCF (ttm): -131.6M
FCF/share: -$0.98
Book value/share: $6.842020-12 $2.772026-06 $6.84+146.8% over the window
ROE: -38.51%2020-12 -44.7%2026-06 -38.5%-13.9% over the window
ROA: -31.79%2020-12 -41.6%2026-06 -31.8%-23.6% over the window
Debt / equity: 0.04×2023-09 0.152026-06 0.04-72.9% over the window
Current ratio: 6.952020-12 27.102026-06 6.95-74.4% over the window

Growth (CAGR, ttm) · 10Y

Shares: +76.66%2025-06-30 → 2026-06-3076.1M → 134.4M (+76.6% total)+50.11%2023-06-30 → 2026-06-3039.7M → 134.4M (+238.3% total)+37.46%2021-06-30 → 2026-06-3027.4M → 134.4M (+390.6% total)n/a

Per-share growth (CAGR, ttm) · 10Y

Book value/share: +180.79%2025-06-30 → 2026-06-30$2.44 → $6.84 (+180.6% total)+36.83%2023-06-30 → 2026-06-30$2.67 → $6.84 (+156.2% total)+1.76%2021-06-30 → 2026-06-30$6.27 → $6.84 (+9.1% total)n/a
Price: +169.70%2025-10-16 → 2026-10-16$11.91 → $32.10 (+169.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+123.08%2023-10-16 → 2026-10-16$2.89 → $32.10 (+1010.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-1.85%2021-10-15 → 2026-10-16$35.25 → $32.10 (-8.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+25.50%2016-11-15 → 2026-10-16$3.38 → $32.10 (+851.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +169.70%2025-10-16 → 2026-10-16$11.91 → $32.10 (+169.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+123.08%2023-10-16 → 2026-10-16$2.89 → $32.10 (+1010.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-1.85%2021-10-15 → 2026-10-16$35.25 → $32.10 (-8.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+25.50%2016-11-15 → 2026-10-16$3.38 → $32.10 (+851.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -9.2×2021-06 -41.762026-10 -12.20-70.8% over the window
Fwd P/E: -19.0×
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 4.7×2021-06 8.262026-10 4.70-43.1% over the window
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: -3.05%
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 134.4M ÷ 76.1M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -76.66%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-76.66%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($493.8M). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -76.66%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($4.3B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2021-12 -14.1%2026-06 0.0%-100.0% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($4.3B). Same caveat as the cash buyback yield.: 0.00%2021-12 -14.1%2026-06 0.0%-100.0% over the window

Vs own 10Y history

P/B: 72nd

Bar = where today’s multiple sits in DFTX’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-6.30%

-13.01%

-15.19%

-27.21%

YTD

+139.73%

+169.52%

-8.94%

Financial statements

Open full DFTX financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

DFTX — Definium Therapeutics Inc. price, chart and key statistics